title: Initiation of antiretroviral therapy before 6 months of age is associated with faster growth recovery in South African children perinatally infected with human immunodeficiency virus.
abstract: OBJECTIVE
  To describe the effects of age at antiretroviral therapy (ART) initiation on growth outcomes among children infected with HIV followed for 48 months after treatment initiation.
  
  
  METHODS
  This secondary analysis describes anthropometric changes in children infected with HIV in Johannesburg, South Africa who initiated ritonavir-boosted lopinavir-based ART before 24 months of age and were randomized to continue ritonavir-boosted lopinavir or to receive nevirapine after achieving and maintaining virologic suppression. Weight, height, and head circumference were measured at visits over 48 months post-ART initiation. Growth patterns including weight-for-age z-scores (WAZs), height-for-age z-scores, body mass index-for-age z-scores, and head circumference for age z-score were compared between children initiating ART<6 months, 6-12 months, and 12-24 months of age.
  
  
  RESULTS
  A total of 195 children (mean±SD age 10.7±5.9 months), including 54 (27.7%)<6 months, 69 (35.4%) 6-12 months, and 72 (36.9%) 12-24 months of age at ART initiation, were evaluated. In the first 12 months on treatment, children<6 months of age at ART initiation experienced more rapid improvement in WAZ (1.98 vs 1.44, P=.084) and head circumference for age z-score (1.24 vs 0.45, P=.004) than children who initiated ART between 12-24 months of age. By 48 months on ART, growth outcomes were similar, regardless of age at ART initiation. WAZ approached population norms by 12 months on ART. Although improving, height-for-age z-scores remained on average 1.0 z-score below population norms at 48 months of therapy.
  
  
  CONCLUSIONS
  Initiation of ART before 6 months of age results in more rapid growth recovery in children infected with HIV. These data provide further evidence for the importance of prompt diagnosis and early initiation of ART for infants infected with HIV.
authors: Gertrude H. Sergievsky Center, College of Physicians and Surgeons, Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY 10032, USA.
authors: Stephanie
authors: S
authors: Shiau
authors: Stephen
authors: S
authors: Arpadi
authors: Renate
authors: R
authors: Strehlau
authors: Leigh
authors: L
authors: Martens
authors: Faeezah
authors: F
authors: Patel
authors: Ashraf
authors: A
authors: Coovadia
authors: Elaine J
authors: EJ
authors: Abrams
authors: Louise
authors: L
authors: Kuhn
mesh_terms: D000367:Age Factors; D000886:Anthropometry; D044966:Anti-Retroviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use*; D061466:Lopinavir / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D019438:Ritonavir / Q000008:administration & dosage / Q000627:therapeutic use*; D013019:South Africa; D018119:Stavudine / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D044966:Anti-Retroviral Agents; D061466:Lopinavir; D019259:Lamivudine; D018119:Stavudine; D019438:Ritonavir